Hyperfine Inc Dossier
Qualitative Analysis
Business overview
Hyperfine, Inc. (NASDAQ: HYPR) is a pioneering medical technology company that has redefined brain imaging by developing Swoop®, the first FDA-cleared portable, ultra-low-field (ULF) magnetic resonance imaging (MRI) system. Powered by its proprietary Optive AI™ software, the Swoop® system delivers high-quality bedside brain imaging, making MRI accessible, affordable, and clinically relevant directly at the point of care, such as intensive care units, emergency departments, and pediatric clinics. The company operates in a single business segment focused on the production, supply, service, and commercialization of its portable MRI platform.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Commercialization of the redesigned second-generation Swoop® portable MRI scanner and the proprietary Optive AI™ software, which delivers a step-change in image resolution, noise cancellation, and usability.
Expected impact: Aims to accelerate adoption across hospitals, critical care units, emergency departments, and neurology offices by offering diagnostic-quality images approaching conventional 1.5T scanners.
Expanding the commercial footprint of the Swoop® system globally, highlighted by regulatory approvals in India (CDSCO) and European CE/UKCA marks.
Expected impact: Opens up large new geographic markets, establishing Hyperfine as a global leader in portable bedside brain imaging.
Conducting and publishing clinical studies (such as PRIME, Contrast PMR, and NeuroPMR) to demonstrate the clinical utility, diagnostic accuracy, and health economic benefits of the Swoop® system.
Expected impact: Provides the clinical validation necessary to drive mainstream medical adoption, support regulatory submissions, and demonstrate cost savings for healthcare systems.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Awarded a $3.7 million grant to advance global brain health, supporting clinical validation and deployment of portable MRI technology in resource-limited settings.
Terms: $3.7 million in grant funding.
Secured a $40 million senior secured term loan facility to bolster the balance sheet and extend the cash runway into 2028, supporting commercial growth.
Terms: $40 million total facility, with $15 million funded at closing in March 2026 and an additional $25 million available in tranches upon achieving commercial milestones.